Basel, Switzerland and Potsdam, Germany, 2005/11/01

Basel, Switzerland and Potsdam, Germany – Genedata AG, a global provider of computational solutions for drug discovery announced today that they have licensed their Genedata Expressionist® software solution to Signature Diagnostics AG. The leading-edge diagnostics company will use Genedata’s software to help them identify unique gene expression profiles found in colorectal cancer (CRC) patients.

“We needed a scalable, regulatory-compliant solution to accommodate our high-throughput diagnostic clinical discovery efforts”, says Professor André Rosenthal, CEO, Signature Diagnostics AG. The software will be used to process and analyze Affymetrix GeneChip data from thousands of CRC patients receiving treatment at dozens of specialized oncology clinics. Using powerful proprietary algorithms, the goal is to identify unique gene expression signatures that predict the risk of recurrence and response to therapy of individual patients. “Genedata offers the only industrial-scale solution to automate the entire workflow from sample management to statistical analysis and biological interpretation.”

“Signature Diagnostics brings tremendous expertise in molecular diagnostics to the challenge of cancer biomarker discovery”, says Dr Othmar Pfannes, CTO of Genedata AG. Genedata Expressionist® facilitates tight integration between data, analysis and biomedical knowledge. Companies scaling up their expression analysis operations quickly encounter the need for automation and standardization. “This is where a platform like Expressionist comes into its own.”

Contact:
Genedata AG
Dr Tobe Freeman
Marketing Communications
Phone +41 61 697 8510
Fax +41 61 697 7244
Tobe.Freeman@genedata.com
www.genedata.com

Signature Diagnostics AG
Prof. Dr. André Rosenthal
CEO
Phone +49 331 620 7575
Fax +49 331 620 7579
andre.rosenthal@signature-diagnostics.de
www.signature-diagnostics.de

Related Files:

Download in pdf format